Onderzoeksgraad Felvizumab

Felvizumab[HuRSV19VHFNS/VK, RSHZ19, RSVmonoclonalantibody, SB209763]isahumanisedmonoclonalantibody (IgG1) preparedbythehumanizationofanFprotein-specificmurineMAb.Ininvitrostudies, palivizumab, anotherhumanizedMabspecificfortheFproteinofRSV, was4to5-foldmorepotentthanfelvizumabinneutralisingRSV (Scott,1999) .RSHZ19 (Felvizumab) RSVThisantibodywas

SB209763, HuRSV19VHFNS/VK, RSHZ19monoclonalantibody, SB209763, CAS:167747-20-8

Mammalian Cells

F, FusionglycoproteinF0, FusionglycoproteinF2, p27, Interveningsegment, Pep27, Peptide27, FusionglycoproteinF1

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -592°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

HRSV-A

IgG1, kappa